Nuvation Bio Inc. (NUVB) Form 424B5 — Jun 25, 2026
Nuvation Bio Inc. has filed a preliminary prospectus supplement to offer $200 million in aggregate principal amount of convertible senior notes due 2032, with a 30-day option for underwriters to purchase up to an additional $30 million. The notes will be unsecured senior obligations that rank junior to secured debt but senior to subordinated indebtedness. The company plans to use the net proceeds to repay approximately $58.5 million of obligations under its existing senior secured Loan Agreement, pay for capped call transactions to mitigate dilution, and fund general corporate purposes.
Key figures
- Debt Amount
- $200,000,000
- Cash Position
- $533,729,000
- Greenshoe amount
- $30,000,000
- Stock price reference
- $6.46
- Secured loan repayment
- $58,500,000
- Existing revenue interest liability
- $159,800,000
Price after filing
Close on the filing date to close N calendar days later (from $5.81). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.